Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria

• Status: Withdrawn
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall goal is to validate efficacy and potential superiority of dried leaf Artemisia annua (DLA) vs. artemisinin combination therapy (ACT) to cure malaria and to demonstrate elimination of the transmission stage (gametocytes) of the disease. This is a 3 arm trial in Democratic Republic of Congo covering 600 total adult and pediatric patients. Final validation of infection from dried blood samples will be done at WPI.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Worcester Polytechnic Institute
• Collaborators: HEAL Africa Hospital, Goma, Democratic Republic of Congo; Plesion International, Coatesville, PA; Rwanguba Reference Hospital, Rwanguba, Democratic Republic of Congo
• Treatments: Artemether; Artemether-lumefantrine combination; Artemether, Lumefantrine Drug Combination; Artemisinine; Artemisinins; Lumefantrine

Criteria

Inclusion Criteria:

• Positive RDT for malaria and

• Positive blood smear for malaria.

Exclusion Criteria:

• All pregnant mothers less than 12 weeks gestational age.

• Children weighing less than 5 kg.

• Patients who have taken any antimalarial immediately prior to study admission.

• All patients with any form of severe malaria.